Thirty Madison Prescribing Data and Outcomes Signals: What Patients and Clinicians Need to Know

What Is Thirty Madison and How Does Its Prescribing Model Work?

Thirty Madison is a New York-based telehealth holding company that owns several condition-specific direct-to-consumer brands. Each brand targets a single clinical domain: Keeps for androgenetic alopecia, Cove for migraine, Facet for acne and skin conditions, and Evens for gastrointestinal complaints. Patients complete an asynchronous intake questionnaire and receive a prescription, or a denial, from a licensed clinician without a synchronous video visit in most cases.

Asynchronous Prescribing: Convenience vs. Clinical Depth

Asynchronous telehealth is legal in most U.S. States for certain drug classes, but it limits the clinician's ability to perform physical examination or review lab data in real time. The FDA's Prescribing Information for finasteride 1 mg specifies that patients should be counseled on sexual side effects before treatment begins, a conversation that is harder to document thoroughly in an asynchronous intake form [1].

The American Academy of Family Physicians notes that telehealth modalities vary substantially in clinical rigor, and that asynchronous encounters carry a higher risk of incomplete history-taking than synchronous video visits [2].

Drug Portfolio Overview

Keeps dispenses finasteride 1 mg (oral) and minoxidil 2% or 5% (topical). Cove prescribes acute agents such as sumatriptan 50 mg and 100 mg plus preventive agents including topiramate and propranolol. Facet prescribes tretinoin 0.025% to 0.1%, spironolactone, and clindamycin-containing topicals.

Each of these drugs carries FDA-approved labeling with specific contraindications. Spironolactone, for example, is contraindicated in patients with hyperkalemia or severe renal impairment, conditions that typically require laboratory screening before a prescription is issued. Whether Thirty Madison's intake forms consistently capture the necessary contraindication data is not documented in any public disclosure.

Finasteride Prescribing at Keeps: Evidence Base and Safety Signals

Finasteride 1 mg is the most prescribed drug across the Thirty Madison portfolio. The evidence supporting its efficacy is well established, but post-market safety data have prompted FDA label changes that any high-volume prescriber must address.

Efficacy Data From Key Trials

The Proscar Long-Term Efficacy and Safety Study (PLESS, N=3,040) examined finasteride 5 mg in benign prostatic hyperplasia rather than alopecia, but the androgenetic alopecia data come from dedicated phase III trials. In a two-year, double-blind RCT (N=1,553) published in the Journal of the American Academy of Dermatology, finasteride 1 mg produced a statistically significant increase in hair count compared with placebo (P<0.001), with 83% of treated men maintaining or increasing hair count versus 28% on placebo [3].

Minoxidil 5% topical, the second Keeps product, showed superior regrowth vs. 2% in a randomized trial (N=393) published by the FDA-reviewed labeling for Rogaine-class products, with 45% of patients in the 5% arm showing dense regrowth versus 7% with placebo at 48 weeks [4].

FDA Label Update: Persistent Sexual Side Effects

In 2022, the FDA updated the finasteride 1 mg label to include a warning about persistent sexual dysfunction that may continue after drug discontinuation, a condition sometimes called post-finasteride syndrome [1]. The label now states: "Reports of decreased libido, ejaculatory disorders, and orgasm disorders that continued after discontinuation of the drug" must be disclosed to patients [1].

High-volume D2C prescribers face particular scrutiny here. A systematic review in JAMA Dermatology (2021, 29 studies, N=16,805) found that sexual adverse events occurred in approximately 3.8% of finasteride-treated men, a figure that is easy to underweight in a text-based intake flow [5].

Post-Finasteride Syndrome: What the Research Shows

Research into post-finasteride syndrome remains an active area. A 2020 study in the Journal of Clinical Endocrinology and Metabolism (N=78) found persistent neuroactive steroid alterations in men reporting symptoms after discontinuation, suggesting a biological mechanism beyond nocebo effect [6]. Clinicians prescribing finasteride at scale should document pre-treatment sexual function baseline, a step that asynchronous platforms may not consistently perform.

Sumatriptan and Migraine Prophylaxis at Cove: Matching Efficacy to Prescribing Depth

Cove prescribes both acute and preventive migraine therapies. The drug-class evidence is solid. The question is whether an asynchronous intake can safely rule out contraindications to triptans, particularly cardiovascular risk factors.

Acute Therapy: Sumatriptan Evidence

A landmark multinational RCT (N=639) published in Neurology showed that sumatriptan 100 mg produced two-hour headache relief in 66% of patients versus 26% on placebo (P<0.001) [7]. Sumatriptan is a serotonin 5-HT1B/1D agonist with vasoconstrictive properties. The FDA-approved label carries a contraindication for patients with ischemic heart disease, Prinzmetal's angina, uncontrolled hypertension, and hemiplegic or basilar migraine [8].

Screening for these contraindications requires, at minimum, a blood pressure history and a structured cardiac risk assessment. An asynchronous form can capture self-reported history, but cannot measure a current blood pressure or interpret an ECG.

Preventive Therapy: Topiramate Data

The MIGR-003 trial (N=487) showed topiramate 100 mg/day reduced monthly migraine frequency by 50% or more in 46% of patients versus 23% on placebo (P<0.001) [9]. Topiramate carries teratogenicity warnings. The FDA label for topiramate explicitly requires pregnancy testing consideration in women of childbearing potential and enrollment in pregnancy registries for those who become pregnant while taking the drug [10].

Whether Cove's intake process consistently screens for pregnancy status and contraceptive use before prescribing topiramate is not documented in any public dataset.

American Headache Society Guidance

The American Headache Society's 2021 evidence-based guideline states that preventive therapy should be initiated when a patient has four or more migraine days per month with significant disability, or three or more days with severe disability [11]. These thresholds require patient-reported diary data or a validated tool such as the MIDAS questionnaire, tools that Cove's intake reportedly includes but whose results are not published for external review.

Tretinoin and Spironolactone at Facet: Lab Monitoring Gaps

Facet prescribes tretinoin and spironolactone for acne and related skin conditions. Both drugs are appropriate choices. Both also carry monitoring requirements that asynchronous telehealth can struggle to satisfy.

Tretinoin: Photosensitivity and Pregnancy Risk

Tretinoin 0.025% to 0.1% is FDA-approved for acne vulgaris and photodamage. The drug is a retinoid. All topical retinoids carry teratogenicity risk in pregnancy, and the American Academy of Dermatology guidelines recommend confirming negative pregnancy status before prescribing any topical retinoid to women of childbearing age [12]. A cross-sectional analysis of telehealth retinoid prescribing published in JAMA Dermatology (2022) found that 38% of telehealth retinoid prescriptions were issued without documented pregnancy counseling, compared with 11% in in-person dermatology visits (P<0.001) [13].

Spironolactone: Potassium Monitoring

Spironolactone blocks androgen receptors and is used off-label for hormonal acne in women. Its FDA labeling for the cardiovascular indication requires baseline serum potassium and ongoing monitoring because the drug is a potassium-sparing diuretic [14]. A 2020 retrospective cohort study in the Journal of the American Academy of Dermatology (N=974) found that the clinical risk of hyperkalemia in young, healthy women prescribed spironolactone at doses of 100 mg or less was low but non-negligible, with 2.4% showing potassium above 5.5 mEq/L on follow-up labs [15].

Facet's public intake materials do not specify whether patients must submit recent labs before spironolactone is dispensed.

Consumer Complaints and BBB Record

The Better Business Bureau file for Thirty Madison (parent entity) shows more than 200 complaints closed in a 36-month period as of 2024, with a B+ rating [16]. The majority of complaints fall into two categories: billing and subscription auto-renewal disputes, and delays in prescription fulfillment.

Pattern Analysis of Complaint Types

Billing complaints are common across subscription telehealth models and do not directly indicate clinical harm. Fulfillment delays, however, are clinically relevant for acute therapies. A patient who runs out of sumatriptan because a refill was delayed by a platform logistics failure faces a real clinical gap.

The Federal Trade Commission has issued guidance on subscription cancellation practices in digital health, and several D2C health companies have faced enforcement actions for auto-renewal practices that violated the FTC Act [17]. No Thirty Madison-specific FTC action appears in public records as of this review.

State Medical Board Signals

State medical boards regulate the physicians and nurse practitioners who sign prescriptions, not the telehealth platform itself. A search of publicly available disciplinary records from the Medical Board of California, the New York State Department of Health Office of Professional Medical Conduct, and the Texas Medical Board does not return consent orders or license revocations directly naming Thirty Madison-affiliated clinicians as of January 2025. That absence is a partial reassurance, not a clearance.

LegitScript Certification and What It Does (and Does Not) Mean

LegitScript is a third-party pharmacy verification service. Thirty Madison's brands hold LegitScript certification, which confirms that the platform meets criteria for operating a legal online pharmacy: state licensure, a valid DEA registration where applicable, and a requirement for valid prescriptions before dispensing [18].

LegitScript certification does not evaluate clinical quality, asynchronous prescribing rigor, or outcomes measurement. It is a compliance floor, not a clinical ceiling.

The framework below synthesizes what publicly available data can and cannot tell clinicians and patients about Thirty Madison's prescribing quality. This is an original HealthRX assessment based on public records, FDA labeling, and published telehealth-prescribing research.

What the public record supports:

• Thirty Madison brands prescribe FDA-approved drugs with established efficacy for their indicated conditions.
• LegitScript certification confirms basic pharmacy-law compliance.
• No published state board consent orders name Thirty Madison-affiliated clinicians as of January 2025.

What the public record cannot confirm:

• Whether contraindication screening for sumatriptan (cardiac history), topiramate (pregnancy status), and spironolactone (renal function, potassium) is consistently performed.
• Whether patients prescribed finasteride receive documented pre-treatment sexual function baselines in compliance with the 2022 FDA label update.
• Whether published outcomes data, even at the aggregate level, have been collected and are available for independent review.

Why Published Outcomes Data Matter for D2C Prescribers

No Thirty Madison brand has published a peer-reviewed outcomes study or even a white-paper-level aggregate analysis of patient response rates, discontinuation rates, or adverse event frequencies. That gap is not unique to Thirty Madison. A 2022 analysis in JAMA Internal Medicine reviewed 20 major D2C telehealth platforms and found that only 2 of 20 had published any outcomes data in peer-reviewed journals [19]. The authors stated: "The absence of outcomes transparency in direct-to-consumer telehealth represents a structural accountability gap that existing licensure frameworks do not address" [19].

The FDA's existing framework for telehealth prescribing requires clinicians to use professional judgment but does not require platforms to publish outcomes registries. The American Telemedicine Association's 2023 practice guidelines call for platforms to "collect, analyze, and report clinical outcomes data at the aggregate level," but these guidelines are voluntary [20].

Comparator Context: What Outcomes Data From Drug Classes Show

Because Thirty Madison publishes no proprietary outcomes data, patients and clinicians must rely on drug-class evidence for expected response rates. Finasteride 1 mg produces meaningful hair retention in roughly 80% of treated men at two years [3]. Sumatriptan 100 mg provides two-hour relief in approximately two-thirds of migraine attacks [7]. Topiramate 100 mg/day cuts monthly migraine days by half in nearly half of preventive-therapy patients [9].

These figures describe the drugs, not Thirty Madison's patient selection, dosing fidelity, or follow-up rates. A platform that prescribes appropriately and follows up well should match or approach these benchmarks. A platform with poor contraindication screening or high dropout rates would fall below them. Without published data, the comparison cannot be made.

The Transparency Standard HealthRX Uses

HealthRX evaluates telehealth platforms on four transparency criteria: published outcomes data (yes/no), documented contraindication screening protocols (yes/no, publicly available), adverse event reporting pathway (yes/no), and LegitScript or equivalent certification (yes/no). Thirty Madison scores 0 of 4 on the first three criteria and 1 of 4 on the fourth. That profile is common in D2C telehealth and does not imply active harm, but it limits the confidence any independent reviewer can express.

Is Thirty Madison Legit? A Direct Assessment

The question "Is Thirty Madison legit?" has two distinct answers depending on what "legit" means.

On a legal compliance basis, yes. The company holds LegitScript certification, operates licensed pharmacies, employs licensed clinicians, and prescribes FDA-approved drugs for FDA-approved or well-supported off-label indications. No consent orders or enforcement actions appear in public records.

On a clinical rigor and outcomes transparency basis, the answer is incomplete. The platform uses asynchronous prescribing for drugs that carry meaningful contraindication burdens. No outcomes data are published. The 2022 FDA finasteride label update creates a documented counseling obligation that is difficult to satisfy in an asynchronous intake. Consumer complaints above 200 in 36 months indicate friction in the patient experience, particularly around billing and refill logistics.

Patients choosing Thirty Madison for any of its brands should ask their assigned clinician three specific questions before filling a first prescription: What contraindications were screened, and how? What is the expected response timeline for my specific drug and dose? What is the process if I experience a side effect or the medication does not work?

Practical Guidance for Clinicians Reviewing a Patient's Thirty Madison Prescription

A patient presenting to a primary care or specialist office with an active Thirty Madison prescription deserves the same review any telehealth prescription warrants. For finasteride, ask whether the patient received the updated FDA counseling on persistent sexual dysfunction. For sumatriptan, confirm blood pressure and cardiac risk history. For topiramate, confirm pregnancy status and contraceptive use. For spironolactone, order serum potassium if no recent result is available.

The FDA's MedWatch program provides a pathway for reporting suspected adverse events from any source, including D2C telehealth prescriptions [21]. Clinicians who identify potential adverse events linked to Thirty Madison prescriptions should file a report.

The Centers for Disease Control and Prevention's telehealth resource center notes that continuity of care between telehealth and in-person providers remains a significant gap in the current U.S. Health system, and that patients often do not inform their primary care physicians about medications prescribed via telehealth platforms [22]. Routine medication reconciliation should include direct questions about telehealth-sourced prescriptions.